RecruitingNot ApplicableNCT07418125

Studying the Role of Circulating Tumor Cell Clusters in Patients With High-risk Early Breast Cancer, Study GALIA


Sponsor

Institute of Oncology Ljubljana

Enrollment

130 participants

Start Date

Feb 7, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

CTCs, CTC clusters, and ctDNA may predict treatment response and survival in high-risk breast cancer, including IBC.


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

  • Patients with inflammatory breast cancer, regardless of cancer subtype (stage IIID)
  • Patients with non-inflammatory breast cancer: triple-negative and HER2+ subtypes, from stage IIB to IIIA-C
  • Adequate health status for neoadjuvant systemic treatment

Exclusion Criteria7

  • Inflammatory breast cancer stage IV
  • Luminal A, luminal B subtypes of non-inflammatory breast cancer
  • Stages I-IIA breast cancer
  • Inability to understand or communicate in Slovenian
  • Inability to follow protocol instructions
  • Inappropriate health status for chemotherapy treatment
  • Primary treatment with surgery

Interventions

DIAGNOSTIC_TESTLiquid biopsy

Additional liquid biopsy to monitor disease


Locations(1)

Institute of Oncology Ljubljana

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07418125


Related Trials